CLDN18 Recombinant Monoclonal Antibody

Datasheet

Code	CSB-RA005498A2HU
Size	US$210
	Order now
Image	Untransfected KATO3 cells surface (green line), transfected Human CLDN18.2 KATO3 stable cells surface (red line) and transfected Human CLDN18.1 NIH-3T3 stable cells surface (blue line) were stained with anti-CLDN18.2 antibody (2µg/1*10⁶ cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry. The Binding Activity of Human CLDN18.2 with Anti-CLDN18 recombinant antibody. Activity: Measured by its binding ability in a functional ELISA. Immobilized Human CLDN18.2 (CSB-MP005498HU(A5)) at 5 μg/mL can bind Anti-CLDN18 recombinant antibody, the EC₅₀ is 2.947-8.782 ng/mL.
Have Questions?	Leave a Message or Start an on-line Chat

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot No.

P56856

Target Names

CLDN18

Alternative Names

CLDN18; UNQ778/PRO1572; Claudin-18

Species Reactivity

Human

Immunogen

Recombinant Human CLDN18 protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

VHH-hIgG1

Clone No.

25E3

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid

Tested Applications

ELISA, FC

Recommended Dilution

Application	Recommended Dilution
FC	1:50-1:200

Protocols

ELISA Protocol
Flow Cytometry (FC) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

Claudin-18 serves as a critical tight junction protein that maintains epithelial barrier integrity, with particular significance in gastric and pulmonary tissues. The CLDN18.2 isoform has emerged as a highly specific tumor-associated antigen, making it an attractive target for cancer immunotherapy research and diagnostic development. Its restricted expression pattern in normal tissues combined with aberrant expression in gastric, pancreatic, and other adenocarcinomas positions CLDN18 as a compelling focus for therapeutic antibody development and tumor biology studies.

This recombinant monoclonal antibody, clone 25E3, offers the reproducibility essential for longitudinal studies and multi-site collaborations. Because the antibody sequence is defined and production occurs in controlled recombinant systems, researchers can expect consistent performance across lots, eliminating the variability that often complicates experimental comparisons over time.

Validation studies demonstrate this antibody's specificity and functional utility. Flow cytometry analysis using KATO3 cells, both untransfected and stably transfected with human CLDN18.2, confirms selective recognition of the target with clear discrimination between expressing and non-expressing populations. The antibody also recognizes CLDN18.1-transfected NIH-3T3 cells, providing flexibility for researchers working with different isoform expression systems. ELISA binding assays further establish robust target engagement, with EC50 values in the low nanogram per milliliter range when tested against immobilized human CLDN18.2 protein.

The human IgG1 isotype format makes this antibody particularly suitable for researchers developing or characterizing therapeutic candidates, as it mirrors the framework commonly used in clinical antibody development. For investigators exploring CLDN18 biology, tumor targeting strategies, or signal transduction pathways involving tight junction proteins, this antibody provides a reliable tool with demonstrated specificity for human CLDN18.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Customer Reviews and Q&A

■ Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function

Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity.

Gene References into Functions

In this study, we found downregulation of miR-767-3p and upregulation of CLDN18 in lung adenocarcinoma tissue and cell lines. PMID: 29169410
CDH17 and CLDN18 are useful target molecules. Their coupling can aid in the comprehensive detection and localization of gastric cancer metastases in vivo to overcome challenges associated with intratumoral heterogeneity. PMID: 27580354
Bile duct adenocarcinoma cells overexpress claudin-18 via the EGFR/RAS/ERK pathway, contributing to cell proliferation and invasion. PMID: 28624624
The presented data substantiate the hypothesis that claudin-18 is a central barrier-forming component of tight junctions and show that IL-13 downregulates claudin-18. These data also suggest that the loss of claudin-18 is associated with increased sensitization to aeroantigens and airway responsiveness PMID: 27215490
suggest that the reduction of CLDN5, 7, and 18 expression loses the suppressive ability of interaction between PDK1 and Akt and causes sustained phosphorylation of Akt, resulting in the disordered proliferation in lung squamous carcinoma cells PMID: 27884700
Data suggest that claudin-18 suppresses the abnormal proliferation and motility of lung epithelial cells mediated by inhibition of phosphorylation of pyruvate dehydrogenase kinase isoform 1 (PDK1) and proto-oncogene protein c-akt (Akt). PMID: 26919807
Human fetal lungs at 23-24 weeks gestational age, the highest-risk period for developing bronchopulmonary dysplasia, a disease of impaired alveolarization, had significantly lower CLDN18 expression relative to postnatal lungs. PMID: 24787463
Evaluated expression of claudins in gastric cancer and determined their significance for patient outcome. Claudin-3 and claudin-7 were expressed in 25.4% and 29.9% of gastric cancer tissues; 51.5% of gastric cancer tissues had reduced claudin-18. PMID: 24333468
High levels of CLDN18 are associated with non-small-cell lung cancer. PMID: 24710653
Downregulation of miR-1303 can inhibit proliferation, migration and invasion of gastric cancer cells by targeting CLDN18. PMID: 24647998
Claudin-18 positivity is a specific phenotype that is characteristic of intestinal-type Mucinous borderline tumours of the ovary PMID: 23905715
Down-regulation of claudin-18 is associated with the proliferative and invasive potential of gastric cancer. PMID: 24073219
rate of CLDN18.2 positivity is high in pancreatic neoplasms whereby the expression is not limited to the primaries but is also maintained upon metastasis PMID: 23900716
Claudin 10/18 are most commonly expressed in lung adenocarcinomas. Female patients and non-smokers express these claudins more commonly suggesting that they may play a part in the carcinogenesis of tobacco unrelated carcinoma. PMID: 22076167
Claudin 18 (a marker for early carcinogenesis) is commonly expressed in precursor lesions of pancreatic ductal adenocarcinomas. Activation of the protein kinase C pathway might be involved in claudin 18 expression associated with carcinogenesis. PMID: 21832145
Cldn18 is primarily regulated at the transcriptional level via specific protein kinase C signaling pathways and modified by DNA methylation PMID: 21381080
These results suggest that CLDN18 may play an important role in biliary carcinogenesis. PMID: 21607649
High claudin 18 is associated with intraductal papillary mucinous neoplasms of the pancreas. PMID: 21206985
We revealed that claudin-18 expression correlates with poor survival in patients with colorectal cancer and is associated with the gastric phenotype. PMID: 20846265
Loss of claudin expression may enhance the grade of malignancy of gastric cancer in vivo. PMID: 17459057
We conclude that Cldn-18 is the dominant claudin in the TJ of SCE and propose that the change from a Cldn-18-deficient TJ in SqE to a Cldn-18-rich TJ in SCE contributes to the greater acid resistance of BE. PMID: 17932229
Indicate that the PKC/MAPK/AP-1 dependent pathway regulates claudin-18a2 expression in gastric cells. PMID: 18032479
Claudin 18 and annexin A8 are frequently highly overexpressed in infiltrating ductal adenocarcinomas. PMID: 18223320
Claudin 18 staining can aid in diagnosis of gastrointestinal signet ring cell carcinoma. PMID: 18580680
Increased expression of claudin-18 is associated with colitis. PMID: 18831034
CLDN18.2 as a novel, highly attractive pan-cancer target for the antibody therapy of epithelial tumors. PMID: 19047087

Hide All

Subcellular Location

Cell junction, tight junction. Cell membrane; Multi-pass membrane protein.

Protein Families

Claudin family

Tissue Specificity

Isoform A1: Expression is restricted to the lung. Isoform A2: Expression is restricted to the stomach mucosa where it is predominantly observed in the epithelial cells of the pit region and the base of the gastric glands including exocrine and endocrine c

Database Links

HGNC: 2039

OMIM: 609210

KEGG: hsa:51208

STRING: 9606.ENSP00000183605

UniGene: Hs.655324

Promotions

Email: [email protected]
Distributors Worldwide

Service

Phage Display Service

Antibody Service

Protein Service

Gene Synthesis Service

Oligo Synthesis Service

Claudin 18.2, is a 'Dark Horse' in Anti-tumour Therapy? 2021 Insights on the CAR-T Cell Therapy: the Most Popular Targets for Solid Tumor! CLDN6: A "New Favorite" in Targeted Cancer Therapy after CLDN 18.2! CLDN9: Another Key Regulator for Tumors or Hearing Loss from the CLDN Family! CLDN4: A Potential Prognostic Indicator and Therapeutic Target in Tumors！ SLC39A6/ZIP6: a Key Member of Zinc Transporters, a Novel Targeting Antigen of ADC! Mucin-17/MUC17: An Unexpected Target for Tumor Immune Therapy, Notably Gastric Cancer! Bispecific Antibody Overview: From Definition to Application CLDN3: Another Tight Junction Protein or New Drug Target, Interest in CLDN Family is Growing Fast! New Power in the Fight Against Cancer: Spotlight on Rising Stars of ADC Drugs at the 2024 ASCO Annual Meeting Pioneering CAR-T Cell Therapy: Advancing Personalized Cancer Treatment Antibody FAQs What Is an Antibody? How to Choose an Antibody for Scientific Research? The difference between primary antibody and secondary antibod The Meaning of Irregular Antibody Screening Tag Antibodies, Your Good Partner in Protein Research How to Choose the Loading Control Antibodies?

Related pathways

Target Therapy

Call us

301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)

[email protected]

Address

7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA

Join us with

Subscribe newsletter

Leave a message

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Place an order now

I. Product details

Product name *

Code *

Size *

Quantity *

Message

II. Contact details

Name *

Email address *

Company/Organization

Phone

III. Ship To

Address *

City *

State/Province *

Zip/Post code *

Country *

Attn Name *

Phone# *

IV. Bill To Same as Shipping Address